<!DOCTYPE html>
<html lang="zh-CN">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>VEGFA 与寿命关系研究概览</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Noto+Sans+SC:wght@300;400;500;700&display=swap" rel="stylesheet">
    <style>
        :root {
            /* ... Color and Font variables ... */
            --background-color: #f8f8fa;
            --card-bg: #ffffff;
            --text-color: #1d1d1f;
            --secondary-text-color: #4a4a4f;
            --link-color: #007aff;
            --link-hover-color: #0056b3;
            --link-color-deep: #004a99;
            --heading-color: #1d1d1f;
            --border-color: #d8d8dd;
            --highlight-bg: rgba(0, 122, 255, 0.15);
            --positive-icon-color: #34c759; /* Green */
            --negative-icon-color: #ff3b30; /* Red */
            --positive-card-bg: rgba(52, 199, 89, 0.08); /* Very Light Green */
            --negative-card-bg: rgba(255, 59, 48, 0.07); /* Very Light Red */
            --card-shadow: 0 4px 12px rgba(0, 0, 0, 0.07);
            --card-hover-shadow: 0 8px 20px rgba(0, 0, 0, 0.1);
            --border-radius: 12px;
            --system-font: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol";
            --content-font: 'Noto Sans SC', var(--system-font);
            --accent-border-color: var(--link-color);
            --table-header-bg: #f0f2f5;
            --table-row-odd-bg: #f9f9fb;
            --toc-width: 240px;
            --toc-width-margin: 260px;
            --container-max-width: 900px;
            --container-padding-h: 50px;
        }

        html {
             scroll-behavior: smooth;
        }

        body {
            font-family: var(--content-font);
            line-height: 1.7;
            color: var(--text-color);
            background-color: var(--background-color);
            margin: 0;
            padding: 0;
            font-weight: 400;
            -webkit-font-smoothing: antialiased;
            -moz-osx-font-smoothing: grayscale;
            box-sizing: border-box;
        }

        *, *:before, *:after {
            box-sizing: inherit;
        }

        /* *** START: Full-Width Background Header Styling *** */
        .page-header-background {
            width: 100%; /* Full viewport width */
            min-height: 350px; /* Minimum height */
            padding: 80px 20px; /* Vertical padding contributes to height, horizontal for text safety */
            background-image: url('https://haoxiaoru.github.io/newlife.png');
            background-size: cover; /* Cover the area, maintain aspect ratio */
            background-position: center center; /* Center the image */
            background-repeat: no-repeat;
            background-attachment: fixed; /* Parallax effect on desktop */
            position: relative; /* For the overlay pseudo-element */
            display: flex; /* Use flexbox for centering */
            align-items: center; /* Vertically center content (H1) */
            justify-content: center; /* Horizontally center content (H1) */
            text-align: center;
            overflow: hidden; /* Prevent pseudo-element bleed */
            margin-bottom: 40px; /* Space before the main container starts */
            color: #ffffff; /* Default text color for header */
        }

        /* Dark overlay for text readability */
        .page-header-background::before {
            content: "";
            position: absolute;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background-color: rgba(0, 0, 0, 0.55); /* Dark semi-transparent overlay - Adjust opacity as needed */
            z-index: 1; /* Position between background image and text */
        }

        .page-header-background h1 {
             font-family: var(--system-font);
             font-size: 3.2em; /* Prominent size */
             font-weight: 700;
             color: #ffffff; /* White text */
             text-shadow: 2px 2px 8px rgba(0, 0, 0, 0.7); /* Shadow for better readability */
             position: relative; /* Ensure it's above the overlay */
             z-index: 2;
             margin: 0; /* Reset margin */
             padding: 0; /* Reset padding */
             max-width: 900px; /* Limit text width, similar to container */
             line-height: 1.3;
             border: none; /* Remove any previous borders */
             background: none; /* Remove any previous backgrounds */
             scroll-margin-top: 20px; /* Keep scroll margin */
        }
        /* *** END: Full-Width Background Header Styling *** */

        /* Main Content Container - Starts *after* the full-width header */
        .container {
            max-width: var(--container-max-width);
            margin-left: var(--toc-width-margin); /* Still offset by TOC */
            margin-right: auto;
            /* Removed top padding, space is created by header's margin-bottom */
            padding: 0px var(--container-padding-h) 40px var(--container-padding-h); /* Adjust bottom padding */
            position: relative;
        }

        /* General Headings (excluding H1 in background header) */
        h2, h3, h4 {
            font-family: var(--system-font);
            color: var(--heading-color);
            font-weight: 600;
            margin-top: 2em;
            margin-bottom: 1em;
            line-height: 1.3;
            scroll-margin-top: 20px; /* Add space when jumping to headers */
        }
        h2 {
            font-size: 1.8em; font-weight: 600; color: var(--link-color-deep);
            border-bottom: 1px solid var(--border-color); padding-bottom: 0.5em;
        }
        h3 {
            font-size: 1.4em; color: var(--text-color); font-weight: 600;
            border-bottom: none; margin-top: 1.8em;
        }
        h4 {
            font-size: 1.1em; color: var(--secondary-text-color); font-weight: 600;
            border-bottom: none; margin-top: 1.5em; margin-bottom: 0.6em;
        }

        /* --- Other styles remain largely the same --- */
        /* General Text & Links */
        p, li {
            font-size: 1rem; margin-bottom: 1.2em;
            color: var(--secondary-text-color); font-weight: 400;
        }
        .card ul li, .card ol li { color: var(--secondary-text-color); }
        a { color: var(--link-color); text-decoration: none; transition: color 0.2s ease, background-color 0.2s ease; }
        a:hover { color: var(--link-hover-color); text-decoration: underline; }
        strong, b { font-weight: 600; color: var(--text-color); }
        .highlight { background-color: var(--highlight-bg); padding: 0.2em 0.5em; border-radius: 6px; font-weight: 500; color: var(--text-color); }

        /* Citations */
        .citation { font-size: 0.8em; vertical-align: super; color: var(--text-color); margin-left: 2px; white-space: nowrap; }
        a.citation-link { font-size: inherit; vertical-align: inherit; color: var(--link-color); text-decoration: none; padding: 0 1px; margin: 0; }
        a.citation-link:hover { text-decoration: underline; color: var(--link-hover-color); }

        /* Summary List */
        .summary-list ul { list-style: none; padding-left: 0; }
        .summary-list li { position: relative; padding-left: 2em; margin-bottom: 1em; }
        .summary-list li::before { content: '•'; position: absolute; left: 0.5em; top: 0.1em; font-size: 1.2em; color: var(--link-color); font-weight: bold; }

        /* Cards */
        .card { background-color: var(--card-bg); border: 1px solid var(--border-color); border-left: 4px solid var(--accent-border-color); border-radius: 0 var(--border-radius) var(--border-radius) 0; padding: 25px 30px; margin-bottom: 30px; box-shadow: var(--card-shadow); transition: box-shadow 0.3s ease, border-color 0.3s ease; }
        .card:hover { box-shadow: var(--card-hover-shadow); border-left-color: var(--link-hover-color); }
        .card h4 { margin-top: 0; } /* Keep card H4 margin reset */

        /* Summary Table */
        .summary-table { width: 100%; border-collapse: collapse; margin-top: 25px; box-shadow: none; border: 1px solid var(--border-color); border-radius: var(--border-radius); overflow: hidden; }
        .summary-table th, .summary-table td { border: none; border-bottom: 1px solid var(--border-color); padding: 15px 18px; text-align: left; font-size: 0.95em; color: var(--secondary-text-color); vertical-align: top; }
        .summary-table th { background-color: var(--table-header-bg); color: var(--text-color); font-weight: 600; border-bottom-width: 2px; }
        .summary-table th:first-child, .summary-table td:first-child { width: 180px; min-width: 180px; white-space: normal; font-weight: 500; }
        .summary-table tbody tr:last-child td { border-bottom: none; }
        .summary-table tbody tr:nth-child(odd) { background-color: var(--table-row-odd-bg); }
        .summary-table tbody tr:hover { background-color: rgba(0, 122, 255, 0.1); }

        /* Reference List */
        .reference-list { list-style-type: decimal; padding-left: 25px; }
        .reference-list li { margin-bottom: 12px; padding-left: 5px; color: var(--secondary-text-color); scroll-margin-top: 20px; transition: background-color 0.5s ease-in-out; }
        .reference-list li::marker { color: var(--secondary-text-color); font-weight: 500; }
        .reference-list a { font-weight: 400; word-break: break-all; }

        /* Dual Role Section */
        .interactive-dual-role { display: flex; justify-content: space-around; align-items: stretch; padding: 20px 0px; margin: 35px 0; background: none; border-radius: var(--border-radius); text-align: center; gap: 20px; }
        .role-card { flex: 1; padding: 25px 20px; border-radius: var(--border-radius); transition: transform 0.2s ease, box-shadow 0.2s ease, background-color 0.2s ease; cursor: default; border: 1px solid var(--border-color); display: flex; flex-direction: column; align-items: center; box-shadow: 0 2px 6px rgba(0,0,0,0.05); }
        .role-card h4 { margin-top: 10px; margin-bottom: 10px; font-size: 1.15em; font-weight: 600; color: var(--heading-color); border-bottom: none; } /* Keep role-card H4 style */
        .role-card p { font-size: 0.95em; color: var(--secondary-text-color); flex-grow: 1; }
        .role-card:hover { transform: translateY(-3px); box-shadow: var(--card-hover-shadow); }
        .role-icon { font-size: 2.8em; margin-bottom: 5px; display: inline-block; line-height: 1; }
        .role-card.positive-role { background-color: var(--positive-card-bg); }
        .role-card.positive-role .role-icon { color: var(--positive-icon-color); }
        .role-card.negative-role { background-color: var(--negative-card-bg); }
        .role-card.negative-role .role-icon { color: var(--negative-icon-color); }

        /* Footer */
        .footer { text-align: center; margin-top: 50px; padding-top: 25px; border-top: 1px solid var(--border-color); font-size: 0.9em; color: #86868b; }

        /* --- Table of Contents Styling (Fixed Left) --- */
        #toc { position: fixed; left: 0; top: 0; width: var(--toc-width); height: 100vh; background-color: var(--card-bg); border-right: 1px solid var(--border-color); padding: 30px 15px 30px 20px; overflow-y: auto; z-index: 1000; transition: transform 0.3s ease, opacity 0.3s ease; }
        #toc h3 { margin: 0 0 20px 0; padding-bottom: 10px; font-size: 1.25em; font-weight: 600; color: var(--heading-color); border-bottom: 1px solid var(--border-color); text-align: left; margin-top: 0; }
        #toc ul { list-style: none; padding: 0; margin: 0; }
        #toc li { margin: 0; padding: 0; line-height: 1.5; }
        #toc li::before { display: none; }
        #toc a { display: block; padding: 6px 10px; margin-bottom: 2px; font-weight: 500; font-size: 0.9em; color: var(--secondary-text-color); text-decoration: none; border-radius: 6px; transition: background-color 0.2s ease, color 0.2s ease; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; }
        #toc a:hover { background-color: var(--highlight-bg); color: var(--link-color); text-decoration: none; }
        #toc a.active { background-color: var(--highlight-bg); color: var(--link-color); font-weight: 600; }
        #toc ul ul { padding-left: 15px; margin-top: 2px; margin-bottom: 5px; }
        #toc ul ul a { font-size: 0.85em; padding-left: 12px; color: var(--secondary-text-color); }
        #toc ul ul ul { padding-left: 15px; margin-top: 2px; margin-bottom: 5px; }
        #toc ul ul ul a { font-size: 0.82em; padding-left: 12px; color: #6e6e73; }
        #toc ul ul a.active, #toc ul ul ul a.active { background-color: var(--highlight-bg); color: var(--link-color); font-weight: 500; }
        /* --- End TOC Styling --- */


        /* --- Responsive Adjustments --- */

        /* Medium screens */
        @media (max-width: 1024px) {
            :root { --toc-width: 200px; --toc-width-margin: 220px; }
            .container { margin-left: var(--toc-width-margin); padding: 0px 40px 30px 40px; } /* Adjust container padding */
            #toc { width: var(--toc-width); padding: 25px 10px 25px 15px; }
            #toc h3 { font-size: 1.15em; }
            #toc a { font-size: 0.88em; padding: 5px 8px; }
            #toc ul ul a { font-size: 0.83em; padding-left: 10px;}
            #toc ul ul ul a { font-size: 0.80em; padding-left: 10px;}
            .summary-table th:first-child, .summary-table td:first-child { width: 120px; min-width: 120px;}
            /* Adjust header */
            .page-header-background { min-height: 300px; padding: 60px 15px; margin-bottom: 30px; }
            .page-header-background h1 { font-size: 2.8em; }
        }

         /* Layout Balancing on Wide Screens (Container only) */
        @media (min-width: 1300px) {
            :root { --container-max-width: 1000px; --container-padding-h: 60px; }
             .container { max-width: var(--container-max-width); margin-left: var(--toc-width-margin); padding-left: var(--container-padding-h); padding-right: var(--container-padding-h); }
             .page-header-background h1 { max-width: 1000px; } /* Match text width limit */
        }
        @media (min-width: 1600px) {
            :root { --container-max-width: 1100px; --container-padding-h: 70px; }
             .container { max-width: var(--container-max-width); margin-left: var(--toc-width-margin); padding-left: var(--container-padding-h); padding-right: var(--container-padding-h); }
            .page-header-background h1 { max-width: 1100px; } /* Match text width limit */
        }

        /* Mobile/Tablet */
        @media (max-width: 768px) {
             html { scroll-padding-top: 70px; } /* Keep for sticky TOC */
             /* Make container full width, remove TOC offset */
             .container { max-width: 100%; margin-left: 0; padding: 0 20px 25px 20px; }
             .interactive-dual-role { flex-direction: column; gap: 15px; }
             .role-card { width: 100%; }

             /* Revert TOC to sticky top bar */
             #toc { position: sticky; top: 0; left: auto; width: auto; height: auto; border-right: none; border-bottom: 1px solid var(--border-color); box-shadow: 0 2px 5px rgba(0,0,0,0.08); padding: 10px 15px; margin: 0; overflow-y: visible; background-color: rgba(255, 255, 255, 0.95); backdrop-filter: blur(10px); -webkit-backdrop-filter: blur(10px); z-index: 1000; }
             #toc h3 { display: none; }
             #toc ul { display: flex; flex-wrap: wrap; justify-content: center; padding: 0; gap: 4px 12px; }
             #toc li { margin: 0; padding: 0; line-height: 1.2; }
             #toc a { display: inline-block; padding: 4px 7px; margin: 0; font-size: 0.82em; border-radius: 4px; white-space: normal; text-overflow: clip; overflow: visible; }
             #toc ul ul { padding-left: 8px; margin: 0; display: inline; }
             #toc ul ul li { display: inline; }
             #toc ul ul a { font-size: 0.8em; padding: 3px 5px; display: inline; margin-left: 5px;}
             #toc ul ul ul { padding-left: 8px; margin: 0; display: inline;}
             #toc ul ul ul li { display: inline;}
             #toc ul ul ul a { font-size: 0.78em; padding: 3px 5px; display: inline; margin-left: 5px;}
             #toc a.active { background-color: var(--highlight-bg); color: var(--link-color); font-weight: 600; }

             /* Adjust table */
             .summary-table th:first-child, .summary-table td:first-child { width: 100px; min-width: 90px; font-weight: normal; }
             .reference-list li { scroll-margin-top: 70px; }

             /* Adjust Background Header for Mobile */
            .page-header-background {
                min-height: 250px; /* Reduce height */
                padding: 50px 15px; /* Reduce padding */
                background-attachment: scroll; /* Disable fixed background on mobile (performance/rendering issues) */
                margin-bottom: 25px; /* Reduce space */
            }
            .page-header-background h1 {
                font-size: 2.4em; /* Adjust H1 size */
                text-shadow: 1px 1px 4px rgba(0, 0, 0, 0.8); /* Adjust shadow slightly */
            }
        }

        /* Small Mobile */
        @media (max-width: 480px) {
             html { scroll-padding-top: 60px; }
             body { font-size: 15px; }
             h2 { font-size: 1.5em; } h3 { font-size: 1.2em; }
             .container { padding: 0 15px 20px 15px; } /* Adjust container padding */
             .card { padding: 20px 15px; border-left-width: 3px; }
             .summary-table th, .summary-table td { padding: 12px 10px; font-size: 0.9em; }
             #toc { padding: 8px 10px; }
             #toc ul { gap: 3px 8px; }
             #toc a { font-size: 0.78em; padding: 3px 5px; }
             .summary-table th:first-child, .summary-table td:first-child { width: 80px; min-width: 70px; }
             .reference-list li { scroll-margin-top: 60px; }
             #toc ul ul a, #toc ul ul ul a { margin-left: 3px; font-size: 0.75em; padding: 2px 4px;}

             /* Adjust Background Header for Small Mobile */
             .page-header-background {
                 min-height: 200px; /* Further reduce height */
                 padding: 40px 10px; /* Further reduce padding */
                 margin-bottom: 20px;
             }
             .page-header-background h1 {
                 font-size: 2em; /* Further reduce H1 size */
             }
        }

    </style>
</head>

<body>
    <!-- TOC Navigation (Remains fixed on desktop) -->
     <nav id="toc">
         <h3>目录</h3>
         <ul>
             <li><a href="#detailed-analysis">一、关键研究</a></li>
             <li><ul><li> <a href="#animal-studies">动物研究 (1篇)</a></li></ul></li>
             <li><ul><li> <a href="#disease-studies">特定疾病研究 (4篇)</a></li></ul></li>
             <li><ul><li> <a href="#human-genetics">人类遗传学研究 (1篇)</a></li></ul></li>
             <li><ul><li> <a href="#cell-studies">细胞研究 (1篇)</a></li></ul></li>
             <li><a href="#discussion">二、研究分析</a></li>
             <li><a href="#conclusion">三、结论要点</a></li>
             <li><a href="#references">四、参考文献</a></li>
         </ul>
     </nav>

    <!-- START: Full Width Background Header -->
    <header class="page-header-background">
        <h1>研究概览：VEGFA 与寿命关系</h1>
        <!-- The img element is removed, it's now a CSS background -->
    </header>
    <!-- END: Full Width Background Header -->

    <!-- Main Content Container (Starts AFTER the header) -->
    <div class="container">

        <section id="overview">
             <p>VEGFA（血管内皮生长因子A）是血管生成的关键蛋白质，对寿命影响复杂：通过维持血管健康可促进健康衰老，但在癌症中则加速肿瘤生长而缩短生存期。这种情境依赖性关系对开发抗衰老和疾病干预策略具有重要意义。</p>
            <!-- Dual Role Section -->
               <div class="interactive-dual-role">
                 <div class="role-card positive-role">
                   <span class="role-icon">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="1em" height="1em" fill="currentColor"><rect x="3" y="10" width="18" height="4" rx="1"/><rect x="10" y="3" width="4" height="18" rx="1"/></svg>
                   </span>
                     <h4>积极作用 (促进长寿)</h4>
                     <p>在健康衰老和特定疾病（如ALS）中，通过改善血管功能、组织维护和神经保护，可能延长健康寿命。</p>
                 </div>
                  <div class="role-card negative-role">
                     <span class="role-icon">
                       <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="1em" height="1em" fill="currentColor"><rect x="3" y="10" width="18" height="4" rx="1"/></svg>
                     </span>
                     <h4>消极作用 (缩短寿命)</h4>
                     <p>在癌症背景下，通过驱动肿瘤血管生成、影响免疫微环境，常常与疾病进展加速和生存期缩短相关。</p>
                 </div>
             </div>
        </section>

        <section id="detailed-analysis">
            <h2>一、关键研究概览</h2>
        </section>

        <section id="animal-studies">
            <h3>动物研究：通过 VEGF 信号传导延长寿命（健康衰老背景）</h3>
            <div class="card">
                <h4>1. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span（抵消与年龄相关的VEGF信号传导不足可以促进健康衰老并延长寿命）</h4>
                <p><strong>研究来源：</strong> Science (2021)</p>
                <p>一项针对老年小鼠的突破性研究证明，增强 VEGF 信号传导可以显著延长寿命。研究人员通过转基因系统或 AAV 病毒载体介导的 VEGF 基因转导，在小鼠体内实现了循环 VEGF 水平的适度、持续升高。</p>
                <ul>
                    <li><b>主要发现：</b>经 VEGF 处理的<b class="highlight">雌性小鼠中位生存期增加了 45%</b>，同时最长寿命也得到延长。</li>
                    <li><b>健康寿命改善：</b>观察到生存曲线的“矩形化”，表明发病期被压缩，健康跨度延长。具体表现为衰老相关病理的减轻，包括脂肪堆积减少、肝脏脂肪变性改善、肌肉减少症缓解、骨质疏松改善、驼背现象减少以及肿瘤负荷降低。</li>
                    <li><b>机制启示：</b>研究强调 VEGF 信号不足可能是多器官衰老的一个核心驱动因素，靶向调控 VEGF 信号具有延长健康寿命的巨大潜力。</li>
                </ul>
                <p><strong>研究链接：</strong>
                    <a href="https://doi.org/10.1126/science.abc8479" target="_blank" rel="noopener noreferrer">DOI: 10.1126/science.abc8479</a> |
                    <a href="https://pubmed.ncbi.nlm.nih.gov/34326210/" target="_blank" rel="noopener noreferrer">PubMed: 34326210</a>
                </p>
            </div>
         </section>

         <section id="disease-studies">
             <h3>特定疾病背景下的研究：VEGF 在 ALS 与癌症中的作用</h3>
             <div class="card">
                 <h4>2. Synergistic Effects of GDNF and VEGF on Longevity and Disease Progression in a Rat Model of Familial ALS（GDNF 和 VEGF 在家族性 ALS 大鼠模型中的协同效应）</h4>
                 <p><strong>研究来源：</strong> Molecular Therapy (2013)</p>
                 <p>这项研究利用人骨髓间充质干细胞 (hMSCs) 作为载体，向家族性肌萎缩侧索硬化症 (ALS) 大鼠模型的肌肉中递送神经营养因子 GDNF 和/或 VEGF。</p>
                 <ul>
                    <li><b>关键发现：</b>单独递送 hMSC-GDNF 或 hMSC-VEGF 均能<b class="highlight">延长 ALS 大鼠的生存期</b>并延缓运动功能恶化。</li>
                    <li><b>协同效应：</b>联合递送 GDNF 和 VEGF 显示出强大的协同作用，比单独递送更能显著延长生存期，并更有效地保护神经肌肉接头 (NMJ) 和运动神经元。</li>
                    <li><b>意义：</b>表明在 ALS 这种神经退行性疾病背景下，通过特定递送方式，VEGF 对寿命具有<b class="highlight">积极的、神经保护性的影响</b>。</li>
                 </ul>
                 <p><strong>研究链接：</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/23712039/" target="_blank" rel="noopener noreferrer">PubMed: 23712039</a></p>
            </div>
             <div class="card">
                 <h4>3. High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients（Galectin-1 和 VEGF 高表达与胃癌患者不良预后相关）</h4>
                 <p><strong>研究来源：</strong> Tumor Biology (2013)</p>
                  <ul>
                     <li><b>关键发现：</b>研究发现胃癌组织中 VEGF-A 和 VEGF-C 的表达水平升高与<b class="highlight">癌症晚期、更易发生转移以及患者生存率降低</b>显著相关。</li>
                     <li><b>推论：</b>这强烈暗示，在该研究的队列中，较高的 VEGF 表达水平很可能与<b class="highlight">胃癌患者的生存期缩短</b>呈负相关。</li>
                     <li><b>机制：</b>这与广泛接受的观点一致，即 VEGF 通过促进肿瘤血管生成，为肿瘤生长和扩散提供“燃料”，从而对癌症预后产生不利影响。</li>
                  </ul>
                 <p><strong>研究链接：</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/24241899/" target="_blank" rel="noopener noreferrer">PubMed: 24241899</a></p>
            </div>
             <div class="card">
                <h4>4. Relationship of VEGF/VEGFR with immune cells and cancer cells: intertwined or forward?（VEGF/VEGFR 与免疫细胞、癌细胞的关系：交织还是驱动？）</h4>
                <p><strong>研究来源：</strong> Journal of Cancer Research (2016)</p>
                <p>这篇综述深入探讨了 VEGF 及其受体 (VEGFR) 信号通路与肿瘤微环境中免疫细胞和癌细胞之间复杂的相互作用网络。</p>
                 <ul>
                    <li><b>多重影响：</b>VEGF 不仅促进血管生成，还能直接或间接影响多种免疫细胞的功能，如抑制树突状细胞 (DC) 的成熟、介导巨噬细胞向肿瘤区域浸润、导致 T 细胞胸腺萎缩、促进调节性 T 细胞 (Treg) 的募集等。</li>
                    <li><b>对癌细胞的作用：</b>VEGF 信号还能增加肿瘤细胞的迁移和侵袭能力，并可能促进癌干细胞特性。</li>
                     <li><b>与生存率的关系：</b>特别指出，受 VEGF 信号影响而浸润到肿瘤中的巨噬细胞数量与<b class="highlight">癌症患者生存率呈显著负相关</b>。</li>
                    <li><b>复杂性：</b>强调了 VEGF 在肿瘤进展中的作用远超简单的“血管开关”，它是一个复杂的信号枢纽，深刻影响着肿瘤免疫逃逸和恶性行为。</li>
                 </ul>
                <p><strong>研究链接：</strong> <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4944543/" target="_blank" rel="noopener noreferrer">PMC: PMC4944543</a></p>
            </div>
            <div class="card">
                <h4>5. Genes That Extend Lifespan May Do So by Mitigating the Increased Risk of Death Posed by Having Hypertension（延长寿命的基因或许是通过降低高血压带来的死亡风险来发挥作用的）</h4>
                <p><strong>研究来源：</strong> American Journal of Hypertension (2023)</p>
                <p>这项研究间接将 VEGF 信号通路与长寿联系起来，特别关注了编码 VEGF 受体1 (VEGFR-1) 的 FLT1 基因。</p>
                <ul>
                    <li><b>核心观点：</b>研究发现，某些与长寿相关的 FLT1 基因型能够<b class="highlight">将高血压患者的死亡风险降低约 17%</b>。</li>
                    <li><b>间接联系：</b>虽然研究焦点是 FLT1，但 VEGFR-1 是 VEGF 的主要受体之一。这表明，参与 VEGF 信号通路的基因变异可能通过减轻心血管疾病（如高血压）带来的风险来促进长寿，从而为 VEGFA 在健康衰老中的潜在益处提供了更广阔的背景。</li>
                </ul>
                <p><strong>研究链接：</strong> <a href="https://academic.oup.com/ajh/article/36/12/631/7240477" target="_blank" rel="noopener noreferrer">AJH: Genes That Extend Lifespan...</a></p>
            </div>
         </section>

         <section id="human-genetics">
            <h3>人类遗传学研究：VEGF 变异性与长寿</h3>
              <div class="card">
                <h4>6. Role of VEGF gene variability in longevity: a lesson from the Italian population（VEGF 基因变异性对长寿的影响：意大利人群研究）</h4>
                <p><strong>研究来源：</strong> Neurobiol Aging (2008) </p>
                <p>这项研究着眼于人类 VEGFA 基因的遗传多态性是否与长寿相关。</p>
                <ul>
                    <li><b>研究设计：</b>分析了 490 名意大利健康受试者（分为年轻/老年组和长寿组 85-99 岁）中 VEGFA 基因启动子区域的四种常见多态性 (-2578C/A, -1190G/A, -1154G/A, -634G/C)。</li>
                    <li><b>主要发现：</b>发现特定等位基因、基因型和单倍型的频率在长寿组中显著更高。例如：
                        <ul>
                            <li>-2578/AA 基因型对比 CC 基因型的比值比 (OR) 为 2.08 (p=0.007)。</li>
                            <li>-1190/AA 基因型对比 GG 基因型的 OR 为 2.01 (p=0.011)。</li>
                            <li>AAGG 单倍型在长寿组中更常见 (14.9% vs. 10.4%, p=0.03)。</li>
                        </ul>
                    </li>
                    <li><b>结论：</b>这些结果表明，<b class="highlight">VEGFA 基因的某些变异与人类长寿存在关联</b>，为 VEGFA 在决定寿命中的作用提供了遗传层面的证据。</li>
                </ul>
                 <p><strong>研究链接：</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/17574707/" target="_blank" rel="noopener noreferrer">PubMed: 17574707</a></p>
             </div>
         </section>

         <section id="cell-studies">
            <h3>细胞研究：VEGFA 与复制寿命</h3>
              <div class="card">
                <h4>7. The VEGFA gene and its putative association with human ageing (VEGFA 基因与人类衰老的潜在关联)</h4>
                <p><strong>研究来源：</strong> Human Ageing Genomic Resources </p>
                <p>细胞层面的研究进一步探索了 VEGFA 对抗衰老的潜力，特别是其对细胞复制性衰老的影响。</p>
                <ul>
                    <li><b>关键发现：</b>在体外培养的人真皮微血管内皮细胞中，补充 VEGFA 能够<b class="highlight">延长其复制寿命</b>。即使在细胞分裂代次较晚时，补充了 VEGFA 的细胞也能在很大程度上维持正常的细胞核形态，延缓了衰老相关的形态学变化。</li>
                    <li><b>支持文献：</b>这一发现得到了 Watanabe 等人早期研究的支持 (Oncogene, 1997, PubMed ID: 9160882)。</li>
                    <li><b>意义：</b>提示 VEGFA 可能通过抑制细胞层面的衰老过程（复制性衰老）来发挥其潜在的抗衰老作用，这对于理解组织再生和开发抗衰老疗法具有启示。</li>
                </ul>
                 <p><strong>信息来源链接：</strong> <a href="https://genomics.senescence.info/cells/gene.php?gene_name=VEGFA" target="_blank" rel="noopener noreferrer">GenAge Database: VEGFA</a></p>
             </div>
         </section>

        <section id="discussion">
            <h2>二、研究分析</h2>
            <table class="summary-table">
                <thead>
                    <tr><th>研究类型</th><th>关键发现</th><th>详情</th></tr>
                </thead>
                <tbody>
                    <tr><td>动物（小鼠, 健康）</td><td>VEGF 信号延长寿命 <b>+45%</b> (雌性)</td><td>中位生存期增加，健康寿命改善（脂肪减少、肿瘤负荷降低等）。<span class="citation">[<a href="#ref1" class="citation-link">1</a>]</span></td></tr>
                    <tr><td>动物（大鼠, ALS）</td><td>干细胞递送 VEGF 可延长生存期</td><td>与 GDNF 联用有协同效应，保护 NMJ 和运动神经元。<span class="citation">[<a href="#ref2" class="citation-link">2</a>]</span></td></tr>
                    <tr><td>人类遗传学</td><td>VEGF 基因变异与长寿相关</td><td>特定基因型 (-2578/AA, -1190/AA) 和单倍型 (AAGG) 在长寿者（85-99岁）中更常见。<span class="citation">[<a href="#ref6" class="citation-link">6</a>]</span></td></tr>
                    <tr><td>人类癌症（胃癌）</td><td>VEGF 高表达很可能与预后不良相关</td><td>推测与生存期缩短相关，驱动肿瘤血管生成。<span class="citation">[<a href="#ref3" class="citation-link">3</a>]</span></td></tr>
                    <tr><td>细胞学</td><td>VEGFA 延长内皮细胞的复制寿命</td><td>补充 VEGFA 可维持细胞正常形态，延缓衰老。<span class="citation">[<a href="#ref7" class="citation-link">7</a>]</span></td></tr>
                    <tr><td>癌症免疫效应</td><td>VEGF 影响免疫细胞，与生存率负相关</td><td>受 VEGF 影响的浸润性巨噬细胞与较差的癌症患者生存率相关。<span class="citation">[<a href="#ref4" class="citation-link">4</a>]</span></td></tr>
                    <tr><td>人类遗传学 (FLT1)</td><td>长寿相关 FLT1 变异降低高血压死亡风险</td><td>间接联系 VEGF 信号通路与心血管健康及长寿。<span class="citation">[<a href="#ref5" class="citation-link">5</a>]</span></td></tr>
                </tbody>
            </table>
             <p>综合多项研究 <span class="citation">[<a href="#ref1" class="citation-link">1</a>-<a href="#ref7" class="citation-link">7</a>]</span>，VEGFA的作用具有多面性和情境依赖性。其在生理状态下促进健康和长寿 <span class="citation">[<a href="#ref1" class="citation-link">1</a>, <a href="#ref2" class="citation-link">2</a>, <a href="#ref5" class="citation-link">5</a>, <a href="#ref6" class="citation-link">6</a>, <a href="#ref7" class="citation-link">7</a>]</span>，而在癌症等病理条件下则推动疾病进展 <span class="citation">[<a href="#ref3" class="citation-link">3</a>, <a href="#ref4" class="citation-link">4</a>]</span>。这表明未来研究和应用需采用精准靶向策略，充分利用其益处，同时抑制其在疾病中的负面影响。</p>
        </section>

         <section id="conclusion">
             <h2>三、结论要点</h2>
               <div id="core-points" class="summary-list card" style="background-color: var(--background-color); border: none; border-left: 4px solid var(--link-color-deep); box-shadow: none; padding: 5px 0 5px 30px;">
                 <ul>
                     <li>研究表明 VEGFA 可能影响寿命，但其效果（积极或消极）因具体情况（健康衰老、神经退行性疾病、癌症）而异。<span class="citation">[<a href="#ref1" class="citation-link">1</a>, <a href="#ref2" class="citation-link">2</a>, <a href="#ref3" class="citation-link">3</a>, <a href="#ref4" class="citation-link">4</a>]</span></li>
                     <li>增强 VEGF 信号传导<b class="highlight">很可能延长健康衰老个体及 ALS 患者的寿命</b>，小鼠实验中观察到中位生存期显著增加（例如，雌性小鼠增加 45%）。<span class="citation">[<a href="#ref1" class="citation-link">1</a>, <a href="#ref2" class="citation-link">2</a>]</span></li>
                     <li>证据倾向于表明，在癌症（特别是胃癌）中，较高的 VEGF 表达与<b class="highlight">较短的寿命相关</b>，因其促进肿瘤血管生成和进展。<span class="citation">[<a href="#ref3" class="citation-link">3</a>, <a href="#ref4" class="citation-link">4</a>]</span></li>
                      <li>遗传学研究显示 VEGFA 基因的某些变异与人类长寿相关 <span class="citation">[<a href="#ref6" class="citation-link">6</a>]</span>，且其受体 FLT1 的长寿相关变异可降低高血压风险 <span class="citation">[<a href="#ref5" class="citation-link">5</a>]</span>，提示<b class="highlight">VEGF 信号通路在健康衰老中的作用</b>。</li>
                     <li>VEGFA 的作用存在争议：其在癌症中的角色使其长寿效益复杂化 <span class="citation">[<a href="#ref3" class="citation-link">3</a>, <a href="#ref4" class="citation-link">4</a>]</span>，但在 ALS 等疾病中则显示出保护效果 <span class="citation">[<a href="#ref2" class="citation-link">2</a>]</span>，凸显了<b class="highlight">情境依赖性</b>。<span class="citation">[<a href="#ref1" class="citation-link">1</a>-<a href="#ref7" class="citation-link">7</a>]</span></li>
                 </ul>
             </div>
             <p>总之，动物模型、人类遗传学和特定疾病研究均表明，VEGFA在调节寿命方面具有复杂且重要的作用，其效果高度依赖于具体情境。它既能促进健康衰老和某些疾病的长寿与健康，又可能加速癌症（如胃癌）进展并缩短生存期。本概览梳理了现有研究，强调未来利用VEGFA进行干预或治疗时，需采取平衡且精准的策略。</p>
         </section>

        <section id="references">
            <h2>四、参考文献</h2>
            <ol class="reference-list">
                 <li id="ref1"><strong>Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span</strong><br><a href="https://pubmed.ncbi.nlm.nih.gov/34326210/" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/34326210/</a></li>
                <li id="ref2"><strong>Synergistic Effects of GDNF and VEGF on Longevity and Disease Progression in a Rat Model of Familial ALS</strong><br><a href="https://pubmed.ncbi.nlm.nih.gov/23712039/" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/23712039/</a></li>
                <li id="ref3"><strong>High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients</strong><br><a href="https://pubmed.ncbi.nlm.nih.gov/24241899/" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/24241899/</a></li>
               <li id="ref4"><strong>Relationship of VEGF/VEGFR with immune cells and cancer cells: intertwined or forward?</strong><br><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4944543/" target="_blank" rel="noopener noreferrer">https://pmc.ncbi.nlm.nih.gov/articles/PMC4944543/</a></li>
               <li id="ref5"><strong>Genes That Extend Lifespan May Do So by Mitigating the Increased Risk of Death Posed by Having Hypertension</strong><br><a href="https://academic.oup.com/ajh/article/36/12/631/7240477" target="_blank" rel="noopener noreferrer">https://academic.oup.com/ajh/article/36/12/631/7240477</a></li>
               <li id="ref6"><strong>Role of VEGF gene variability in longevity: a lesson from the Italian population</strong><br><a href="https://pubmed.ncbi.nlm.nih.gov/17574707/" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/17574707/</a></li>
                <li id="ref7"><strong>The VEGFA gene and its putative association with human ageing (GenAge Database)</strong><br><a href="https://genomics.senescence.info/cells/gene.php?gene_name=VEGFA" target="_blank" rel="noopener noreferrer">https://genomics.senescence.info/cells/gene.php?gene_name=VEGFA</a></li>
            </ol>
        </section>

        <footer class="footer">
            <p>报告生成时间：<span id="generation-time"></span></p>
            <p>由 Kimi Koder 精心整理与可视化呈现</p>
        </footer>

    </div> <!-- End .container -->

    <script>
        // Set generation time
        document.getElementById('generation-time').textContent = new Date().toLocaleString('zh-CN', { dateStyle: 'long', timeStyle: 'short'});

        // --- Smooth Scrolling & Active Link Highlighting ---
        const tocLinks = document.querySelectorAll('#toc a[href^="#"]');
        const citationLinks = document.querySelectorAll('a.citation-link[href^="#"]');
        const sections = document.querySelectorAll('section[id], h3[id]'); // Observe sections and H3s with IDs

        function highlightElement(element) {
            if (!element) return;
            const originalTransition = element.style.transition;
            const originalBgColor = element.style.backgroundColor;
            element.style.transition = 'background-color 0.5s ease-in-out';
            element.style.backgroundColor = 'var(--highlight-bg)';
            setTimeout(() => {
                element.style.backgroundColor = originalBgColor;
                 setTimeout(() => { element.style.transition = originalTransition; }, 500);
            }, 1000);
        }

        function smoothScrollTo(targetElement) {
            if (!targetElement) return;

            const tocElement = document.getElementById('toc');
            let headerOffset = 20; // Base offset

            if (tocElement && getComputedStyle(tocElement).position === 'sticky' && window.innerWidth <= 768) {
                 headerOffset = tocElement.offsetHeight + 20;
            }

            const elementPosition = targetElement.getBoundingClientRect().top;
            const offsetPosition = elementPosition + window.pageYOffset - headerOffset;

            window.scrollTo({ top: offsetPosition, behavior: "smooth" });

             window.requestAnimationFrame(() => {
                setTimeout(() => highlightElement(targetElement), 50);
             });
        }

        tocLinks.forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                e.preventDefault();
                const targetId = this.getAttribute('href').substring(1);
                const targetElement = document.getElementById(targetId);
                smoothScrollTo(targetElement);
            });
        });

        citationLinks.forEach(link => {
            link.addEventListener('click', function (e) {
                e.preventDefault();
                const targetId = this.getAttribute('href').substring(1);
                const targetElement = document.getElementById(targetId);
                smoothScrollTo(targetElement);
            });
        });

        // --- Active link highlighting on scroll (Intersection Observer) ---
         const observerOptions = {
             root: null,
             rootMargin: "-25% 0px -65% 0px", // Adjusted margins
             threshold: 0
         };

        let currentActiveLink = null;

         const observer = new IntersectionObserver(entries => {
             let bestIntersectingEntry = null;
             entries.forEach(entry => {
                 if (entry.isIntersecting) {
                    const idealFocusPoint = window.innerHeight * 0.25;
                    if (!bestIntersectingEntry || Math.abs(entry.boundingClientRect.top - idealFocusPoint) < Math.abs(bestIntersectingEntry.boundingClientRect.top - idealFocusPoint)) {
                        bestIntersectingEntry = entry;
                    }
                 }
             });

             if (bestIntersectingEntry) {
                 const id = bestIntersectingEntry.target.getAttribute('id');
                 const newActiveLink = document.querySelector(`#toc a[href="#${id}"]`);

                 if (newActiveLink && newActiveLink !== currentActiveLink) {
                     if (currentActiveLink) {
                         currentActiveLink.classList.remove('active');
                         const prevParentLi = currentActiveLink.closest('ul')?.closest('li');
                         if (prevParentLi && !prevParentLi.querySelector('ul li a.active')) {
                             prevParentLi.querySelector('a:first-child')?.classList.remove('active');
                         }
                     }
                     newActiveLink.classList.add('active');
                     const parentLi = newActiveLink.closest('ul')?.closest('li');
                     if (parentLi) {
                          parentLi.querySelector('a:first-child')?.classList.add('active');
                     }
                     currentActiveLink = newActiveLink;

                     // Scroll TOC if needed (desktop only)
                     if (window.innerWidth > 768 && getComputedStyle(document.getElementById('toc')).position === 'fixed') {
                         const toc = document.getElementById('toc');
                         const linkRect = newActiveLink.getBoundingClientRect();
                         const tocRect = toc.getBoundingClientRect();
                         if (linkRect.top < tocRect.top + 10 || linkRect.bottom > tocRect.bottom - 10) {
                             newActiveLink.scrollIntoView({ behavior: 'smooth', block: 'nearest' });
                         }
                     }
                 }
             }
         }, observerOptions);

         sections.forEach(section => { observer.observe(section); });
         const conclusionSection = document.getElementById('conclusion');
         if (conclusionSection) { observer.observe(conclusionSection); }

    </script>

</body>
</html>